Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?
Hypoxia within the tumour microenvironment is correlated with poor treatment outcome after radiation and chemotherapy, and with decreased overall survival in cancer patients. Several molecular mechanisms by which hypoxia supports tumour growth and interferes with effective radiation and chemotherapies are now well established. However, several new lines of investigation are pointing to yet another ominous outcome of hypoxia in the tumour microenvironment: suppression of anti-tumour immune effector cells and enhancement of tumour escape from immune surveillance. This review summarises this important information, and highlights mechanistic data by which hypoxia incapacitates several different types of immune effector cells, enhances the activity of immunosuppressive cells and provides new avenues which help 'blind' immune cells to detect the presence of tumour cells. Finally, we discuss data which indicates that mild thermal therapy, through its physiologically regulated ability to alter vascular perfusion and oxygen tensions within the tumour microenvironment, as well as its ability to enhance the function of some of the same immune effector activities that are inhibited by hypoxia, could be used to rapidly and safely release the tight grip of hypoxia in the tumour microenvironment thereby reducing barriers to more effective immune-based therapies.
Lee
Chen-Ting
CT
Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Mace
Thomas
T
Repasky
Elizabeth A
EA
D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects* / Q000379:methods; D000860:Hypoxia / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D008833:Microcirculation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
Cancer Metastasis Rev. 2007 Jun;26(2):225-39
17440684
Clin Cancer Res. 2007 Apr 1;13(7):2199-206
17404104
J Cancer Res Clin Oncol. 2010 Mar;136(3):447-56
19760195
Cancer Immunol Immunother. 2006 Mar;55(3):292-8
15864585
Int J Hyperthermia. 2004 Mar;20(2):163-74
15195511
Nat Rev Cancer. 2006 Aug;6(8):583-92
16862189
J Leukoc Biol. 2007 Nov;82(5):1322-31
17711975
Free Radic Res. 2007 Jul;41(7):788-97
17577739
Cell Stress Chaperones. 2000 Nov;5(5):458-61
11189452
J Immunol. 2003 Jan 15;170(2):695-702
12517930
Int J Microcirc Clin Exp. 1985;4(1):31-43
2580810
Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):731-44
8690639
Lung. 2009 Sep-Oct;187(5):321-9
19707816
J Immunol. 2003 Dec 15;171(12):6891-9
14662896
Lancet. 2000 Apr 1;355(9210):1119-25
10791373
J Exp Med. 2007 Jul 9;204(7):1543-51
17591856
Nat Rev Immunol. 2003 Dec;3(12):984-93
14647480
Annu Rev Immunol. 1995;13:623-53
7612237
J Immunol. 2009 Jun 15;182(12):7974-81
19494322
Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):253-8
1991686
Nat Rev Neurosci. 2003 Jul;4(7):529-39
12838328
Anticancer Agents Med Chem. 2008 Oct;8(7):790-7
18855580
Breast Cancer Res Treat. 2008 Aug;110(3):465-75
17805961
Med Oncol. 2001;18(4):243-59
11918451
Nature. 2002 Oct 17;419(6908):734-8
12384702
Semin Oncol. 1997 Dec;24(6):626-32
9422259
Br J Radiol. 1953 Dec;26(312):638-48
13106296
Int J Hyperthermia. 1995 May-Jun;11(3):315-22
7636318
Cancer Res. 1996 Oct 1;56(19):4509-15
8813149
Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):365-71
16375690
Int J Hyperthermia. 2007 Sep;23(6):513-27
17952765
Radiother Oncol. 1993 Jan;26(1):45-50
8438086
Cancer Res. 1996 Mar 15;56(6):1194-8
8640796
Recent Results Cancer Res. 1987;104:71-109
3296051
Adv Exp Med Biol. 1984;169:621-9
6731117
Cell Immunol. 2004 Mar;228(1):1-7
15203313
Cancer Res. 1996 Dec 1;56(23):5522-8
8968110
Br J Cancer. 2009 Mar 10;100(5):747-57
19223896
Curr Top Microbiol Immunol. 2006;298:121-38
16329186
J Clin Invest. 2002 Oct;110(7):993-1002
12370277
Int J Hyperthermia. 2005 Dec;21(8):675-7
16338847
J Exp Med. 1984 Aug 1;160(2):369-85
6088661
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):179-85
10656391
Physiol Rev. 1961 Jul;41:521-606
13711528
Cell. 2008 May 30;133(5):775-87
18510923
Nat Rev Cancer. 2008 Jun;8(6):425-37
18500244
Genes Dev. 1998 Jan 15;12(2):149-62
9436976
Radiat Res. 2001 Apr;155(4):515-28
11260653
J Surg Oncol. 1983 Jun;23(2):125-32
6855242
Curr Pharm Des. 2008;14(28):2932-42
18991711
Immunology. 2009 Sep;128(1 Suppl):e237-49
19740309
J Immunol. 2001 Dec 1;167(11):6140-9
11714773
J Immunol. 2001 Sep 1;167(5):2666-70
11509609
Neoplasia. 2009 Oct;11(10):976-86
19794957
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):163-9
8270437
Int J Hyperthermia. 1994 Jul-Aug;10(4):485-93
7525790
Radiat Res. 1998 Mar;149(3):294-9
9496893
Drug Resist Updat. 2009 Jun;12(3):74-80
19394890
Science. 1999 Jul 30;285(5428):727-9
10426993
J Clin Invest. 1982 Sep;70(3):550-7
7107894
Eur J Immunol. 2001 Feb;31(2):480-9
11180113
Oncologist. 2008;13 Suppl 3:21-6
18458121
Radiat Res. 1992 May;130(2):171-82
1574573
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95
9457811
J Nucl Med. 2009 Jun;50(6):942-9
19443598
Radiat Res. 1978 Aug;75(2):373-84
715179
Exp Cell Res. 2004 Oct 1;299(2):476-85
15350545
Curr Opin Genet Dev. 1998 Oct;8(5):588-94
9794818
Med Sci Monit. 2006 Oct;12(10):RA225-34
17006415
J Clin Oncol. 2005 May 1;23(13):3079-85
15860867
Microvasc Res. 2007 Sep-Nov;74(2-3):72-84
17560615
Int J Hyperthermia. 1987 Nov-Dec;3(6):535-45
3693986
Lancet. 1995 Mar 4;345(8949):540-3
7776772
Eur J Cancer. 2008 Dec;44(18):2766-73
18990559
NMR Biomed. 1991 Jun;4(3):117-24
1911098
Oncogene. 2008 Oct 6;27(45):5944-58
18836475
Crit Care Med. 1994 Feb;22(2):197-203
8306676
J Immunol. 2003 Feb 15;170(4):1964-72
12574365
Immunol Today. 1999 Jul;20(7):302-6
10379047
Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):95-101
8641932
Radiology. 1980 Nov;137(2):523-30
7433686
Cancer Res. 1996 Dec 1;56(23):5347-50
8968082
Cancer Res. 2008 Jun 15;68(12):4746-53
18559521
Ann Surg Oncol. 2007 Sep;14(9):2600-7
17534684
Mayo Clin Proc. 2003 May;78(5):603-12
12744548
Trends Immunol. 2008 Aug;29(8):397-403
18602338
Cancer Res. 2006 Jan 15;66(2):1033-9
16424039
Radiother Oncol. 1999 Nov;53(2):113-7
10665787
Cancer Res. 1996 Mar 1;56(5):941-3
8640781
Cancer. 2000 Dec 15;89(12):2646-54
11135227
Cancer Res. 1990 Jun 1;50(11):3339-44
2334928
Int J Hyperthermia. 2008 Feb;24(1):41-56
18214768
Cancer Res. 1984 Oct;44(10 Suppl):4721s-4730s
6467226
Cancer Res. 1989 Aug 15;49(16):4373-84
2545340
J Biol Chem. 2001 Jul 27;276(30):28554-61
11373280
Trends Immunol. 2009 Mar;30(3):102-8
19201652
Int J Hyperthermia. 1985 Oct-Dec;1(4):305-19
2425020
Urology. 2002 Oct;60(4):634-9
12385924
J Exp Clin Cancer Res. 2009 Dec 10;28:150
20003295
Blood. 2004 Oct 15;104(8):2224-34
15231578
Cell Mol Life Sci. 2007 Dec;64(24):3233-47
17957335
Nature. 1992 Oct 29;359(6398):843-5
1279431
Int J Hyperthermia. 1992 May-Jun;8(3):289-95
1607733
J Natl Cancer Inst. 2001 Dec 19;93(24):1879-85
11752013
Annu Rev Immunol. 2004;22:657-82
15032592
Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):843-8
9845108
Int J Cancer. 2009 Nov 1;125(9):2198-204
19623660
Int J Hyperthermia. 2003 Sep-Oct;19(5):520-33
12944167
Br J Cancer. 1955 Dec;9(4):539-49
13304213
Biochem Pharmacol. 2009 Jun 1;77(11):1665-73
19428320
Mol Ther. 2008 Mar;16(3):599-606
18227840
Eur J Immunol. 2008 Sep;38(9):2412-8
18792019
Oncogene. 2009 Nov 12;28(45):3949-59
19718046
Nat Immunol. 2000 Sep;1(3):199-205
10973276
Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):799-802
2777670
Blood. 2003 May 15;101(10):3985-90
12446452
Int J Hyperthermia. 1996 May-Jun;12(3):367-73
9044906
Immunobiology. 2001 Dec;204(5):551-7
11846218
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12445-50
8901601
Nat Rev Immunol. 2009 Sep;9(9):609-17
19704417